Conclusions - A strategy of immediate PCI does not impact the incidence of death or MI in NSTE ACS
Length of hospital stay was significantly reduced with an immediate PCI strategy
ACTIVE A - This study evaluated treatment with a combination of aspirin and clopidogrel versus aspirin alone in patients with AF who were not candidates for warfarin therapy.
Conclusions -Clopidogrel in addition to aspirin may reduce the risk of stroke in patients with AF who are unsuitable candidates for warfarin therapy
The increased risk of major hemorrhage with aspirin + clopidogrel somewhat attenuates this benefit
ARMYDA-RECAPTURE - This study evaluated the efficacy of an atorvastatin reloading strategy in patients on chronic statin therapy undergoing PCI for stable angina or NSTEMI.
Conclusions -An 80 mg loading dose of atorvastatin followed by a 40 mg preprocedural dose may reduce the incidence of post-procedure MACE in patients on background statin therapy
These data support a strategy of routine atorvastatin reloading prior to PCI in patients on background statin therapy
AURORA - This study evaluated treatment with 10 mg rosuvastatin compared with standard therapy in patients with end-stage renal disease receiving hemodialysis
Conclusions - Low-dose rosuvastatin therapy does not reduce the rate of cardiovascular events in patients with ESRD receiving hemodialysis
EARLY ACS - Patients with NSTE ACS were randomized to upstream eptifibatide and 18- to 24-hour infusion (n = 4,722) versus upstream placebo and provisional eptifibatide immediately prior to PCI (n = 4,684).
Conclusions -Among patients with NSTE ACS treated with aspirin, clopidogrel, and heparin, there was no benefit to upstream eptifibatide compared with provisional use immediately prior to PCI
Upstream use of eptifibatide increased major bleeding
FIX-HF-5 Patients with NYHA III or IV heart failure and narrow QRS were randomized to cardiac contractility modulation plus optimal medical therapy (n = 215) vs. optimal medical therapy alone (n = 213).
Conclusions -Among patients with advanced heart failure, low ejection fraction, and narrow QRS, cardiac contractility modulation failed to improve the primary efficacy outcome, anaerobic threshold
Cardiac contractility modulation did improve peak VO2 and quality of life
GENIUS-STEMI Patients with STEMI were randomized to the endothelial progenitor cell capture stent (n = 50) vs. a cobalt-chromium BMS (n = 50). Follow-up was 6 months.
Conclusions - Among patients with STEMI, the endothelial progenitor cell capture stent was inferior to a cobalt-chromium bare-metal stent
This experimental stent resulted in increased MACE, TLR, and stent thrombosis...